Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 9/20 | 0.57 |
| ▸ | AXL | P30530 | 6/20 | 0.55 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 6/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.48 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | FLT4 | P35916 | 4/20 | 0.48 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744533 | 0.96 | MET (0.60) | METAXLFLT3KDREGFR | |
| SCHEMBL5571167 | 0.88 | TRPA1 (0.57) | METAXLKDREGFRFGFR1 | |
| SCHEMBL15338410 | 0.87 | EGFR (0.63) | METAXLFLT3KDREGFR | |
| SCHEMBL15338459 | 0.86 | MET (0.60) | METAXLFLT3KDREGFR | |
| SCHEMBL29693573 | 0.85 | AXL (0.65) | METAXLFLT3KDREGFR | |
| SCHEMBL371859 | 0.85 | AXL (0.65) | METAXLFLT3KDREGFR | |
| SCHEMBL14313726 | 0.84 | MET (0.58) | METFLT3KDREGFRFGFR1 | |
| SCHEMBL2744934 | 0.84 | EGFR (0.57) | METAXLKDREGFRFGFR1 | |
| SCHEMBL2744528 | 0.84 | MET (0.60) | METAXLFLT3KDREGFR | |
| SCHEMBL5411428 | 0.83 | AXL (0.60) | METAXLFLT3KDREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20140155378-A9 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-20130252940-A1 | c-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8497284-B2 | C-met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8476298-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155378-A9 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885FLT3 7/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | MET 3/4885AXL 109/4885FLT3 7/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885FLT3 7/4885 |
| US-20130252940-A1 | c-Met Modulators and Method of Use | FLT4, MET, FLT1 | MET 2/4885AXL 241/4885FLT3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.